LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Tyme Technologies, Inc. to Contact the Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds
investors in Tyme Technologies, Inc. (“Tyme” or the “Company”)
(NASDAQ:TYME) of the March 29, 2019 deadline to seek the role of lead
plaintiff in a federal securities class action that has been filed
against the Company.

If you invested in Tyme stock or options between March 14, 2018 and
January 18, 2019 and would like to discuss your legal rights, click
here: www.faruqilaw.com/Tyme.
There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at
877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].

The lawsuit has been filed in the U.S. District Court for the Southern
District of New York on behalf of all those who purchased Tyme
securities between March 14, 2018 and January 18, 2019 (the “Class
Period”). The case, Canas v. Tyme Technologies, Inc. et al., No.
19-cv-00843 was filed on January 28, 2019, and has been assigned to
Judge Ronnie Abrams.

The lawsuit focuses on whether the Company and its executives violated
federal securities laws by making false and/or misleading statements
and/or failing to disclose that: (1) Tyme had not adequately designed
the Phase II Study to present reliable results on the efficacy of SM-88
on pancreatic cancer; (2) Tyme had failed to include an appropriate
control group in its openlabel Phase II clinical trial for SM-88; (3)
the omission of an appropriate control group distorted the reliability
of data showing the efficacy of SM-88 in the Phase II Study; and (4) as
a result, Tyme’s public statements were materially false and misleading
at all relevant times.

Specifically, on January 18, 2019, Tyme reported results from the Phase
II Study. Although Tyme characterized the results as positive, stating
that SM-88 “improves survival,” the trial did not include a control
group, and Tyme’s announcement merely compared survival data to
historical controls. Market commentators were quick to highlight this
glaring deficiency in the Phase II Study.

On this news, the Company's stock price fell from $3.73 per share on
January 17, 2019 to $2.41 per share on January 18, 2018—a $1.32 or
35.39% drop.

The court-appointed lead plaintiff is the investor with the largest
financial interest in the relief sought by the class who is adequate and
typical of class members who directs and oversees the litigation on
behalf of the putative class. Any member of the putative class may move
the Court to serve as lead plaintiff through counsel of their choice, or
may choose to do nothing and remain an absent class member. Your ability
to share in any recovery is not affected by the decision to serve as a
lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding
Tyme’s conduct to contact the firm, including whistleblowers, former
employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We welcome the opportunity to discuss your
particular case. All communications will be treated in a confidential
manner.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190319005872/en/